A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

Investigational New Drugs

Volumn 33, Issue 2, 2015, Pages 463-471

  Bendell, Johanna C ^a,b,d   Kurkjian, Carla ^a,c   Infante, Jeffrey R ^a,b   Bauer, Todd M ^a,b   Burris, Howard A ^a,b   Greco, F Anthony ^a,b   Shih, Kent C ^a,b   Thompson, Dana S ^a,b   Lane, Cassie M ^a   Finney, Lindsey H ^a   Jones, Suzanne F ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Stephenson Cancer Center   (United States)

^d NONE   (United States)

Author keywords

BEZ235; Dose escalation; PI3K mTOR; Sachet formulation

Indexed keywords

DACTOLISIB; IMIDAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MEDICINAL CHEMISTRY; MIDDLE AGED; NEOPLASMS; PHASE 1 CLINICAL TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; TOR SERINE-THREONINE KINASES;

EID: 84939949523     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0218-6     Document Type: Article

References (22)

1. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772-775
2. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7:561-573
3. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554
4. Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102:802-807
5. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96:4240-4245
6. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184-192
7. Burris H, Rodon J, Sharma S, Herbst RS, Tabernero J, Infante JR, Silva A, Demanse D, Hackl W, Baselga J (2010) First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. ASCO Meet Abstr 28:3005
8. Peyton JD, Rodon Ahnert J, Burris H, Britten C, Chen LC, Tabernero J, Duval V, Rouyrre N, Silva AP, Quadt C, Baselga J (2011) A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. ASCO Meet Abstr 29:3066
9. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4. http://evs.nci.nih.gov/ftp1/CTCAE/About.html, National Cancer Institute (acessed October, 2014)
10. Eisenhauer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
11. Brana I, LoRusso P, Baselga J, Heath EI, Patnaik A, Gendreau S, Laird A, Papadopoulos K (2010) A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. ASCO Meet Abstr 28:3030
12. Hollebecque A, Clamp A, Horsley L, Morgan JA, Bahleda R, George S, Shaw D, Lauchle JO, Ware J, Desai R, Wu J, Fu L, Jayson GC, Soria JC, Wagner AJ 12. Hollebecque A, Clamp A, Horsley L (2011) A phase I study evaluating the pharmokinetics (PK) and pharmodynamics (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW). AACR/NCI/EORTC Molecular Targets and Cancer Therapeutics Meeting Abstract B153
13. Millham R, Houk B, Borzillo G (2011) First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: update on safety, efficacy, and pharmacology. AACR/NCI/EORTC Molecular Targets and Cancer Therapeutics Meeting Abstract B163
14. Munster PN, van der Noll R, Voest EE, Dees EC, Tan AR, Specht JM, Falchook GS, Daud A, Lolkema MP, Grilley-Olson JE, Yu EY, Fu S, Bergsland EK, Kleha J, Peng S, Smith DA, Lampkin TA, Schellens JHM, Morris SR, R. Kurzrock R (2011) Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). ASCO Meeting Abstracts 29:3018
15. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Braña I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C, Edelman G (2014) Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 20:233-245
16. Burris H, Rodon J, Sharma S, Herbst RS, Tabernero J, Infante JR, Silva A, Demanse D, Hackl W, Baselga J (2010) First-in-human phase I study of the oral dual PI3K and mTORC1/2 inhibitor BEZ235 in patients with advanced solid tumors. ASCO Meeting Oral Presentation 3005
17. Hollebecque A, Clamp A, Horsley L (2011) A phase 1 study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW). American Association for Cancer Research, Orlando
18. Millham R, Houk B, Borzillo G (2011) First-in-patient study of PF-049691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: update on safety, efficacy, and pharmacology. AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics San Franciso, CA, Abstract B163
19. Campone M, Fumoleau P, Gil-Martin M, Isambert N, Beck JT, Becerra C, Shtivelband M, Duval V, di Tomaso E, Roussou P, Urban P, Urruticoechea A (2012) A multicenter, open-label Ph IB/II study of BEZ235, an oral dual PI3K/mTOR inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium Abstract:P6-11-08
20. Mayer IA, Abramson VG, Balko JM, Isakoff SJ, Forero A, Kuba MG, Sanders ME, Li Y, Winer E, Arteaga CL (2012) SU2C phase 1b trial of dual PI3K/ mTOR inhibitor BEZ235 with letrozole in ER+/HER2- METASTATIC BREAST CANCER (MBC). San Antonio Breast Cancer Symposium Abstract: P6-10-05
21. Ahnert JR, Schuler MH, Machiels J-P H, Hess D, Paz-Ares L, Awada A, von Moos R, Steeghs N, Zambrano CC, Peggy De Mesmaeker P, Richly H, Herremans C, Joerger M, Jaime JC, Alsina M, Baffert F, Demanse D, Duval V, Morozov A, Dirix L (2014) Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC). ASCO Meet Abstr 32:621
22. Siegel AP, Bryce AH, Lin AM, Friedlander TW, Hsieh AC, Hang E, Weinberg VK, Ryan CJ (2014) Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC). ASCO Meet Abstr 32:e16042